Rutherford Health - Result of AGM
RNS Number : 2484K
Rutherford Health PLC
31 August 2021
 

Rutherford Health Plc

("Rutherford" or "the Company")

Results of AGM

 

 

31 August 2021

 

 

At the Annual General Meeting of the Company held earlier today, shareholders passed the first resolution (the re-appointment of Marcus King as a director) but did not pass the second and third resolutions, being the granting of authorities to directors to issue shares and the disapplication of pre-emption rights.

 

A copy of the resolutions is available on the Company's website, https://www.rutherfordhealth.com . The results of the resolutions, which were taken on a poll, will also be available on the Company's website.

 

 

-Ends-

For more information, please contact:

 

Rutherford Health plc

+44 (0) 16 3381 0661

Michael Moran, Chief Executive Officer
Marcus King, Finance Director

Investors@therutherford.com



Grant Thornton (Corporate Adviser)

+44 (0) 20 7383 5100

Colin Aaronson / George Grainger




Instinctif Partners

+44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris

Rutherford@Instinctif.com



Media House International

07788 414 856 / 0207 710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

 



 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in Wales, Reading, Northumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website: www.rutherfordhealth.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXPBMBTMTAJBRB ]]>